JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

JPMorgan Chase & Co. boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 17.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 297,810 shares of the specialty pharmaceutical company’s stock after buying an additional 44,414 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.54% of Supernus Pharmaceuticals worth $10,769,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SUPN. Barclays PLC boosted its stake in shares of Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Franklin Resources Inc. boosted its position in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after buying an additional 2,121 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $1,498,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Price Performance

SUPN opened at $31.60 on Tuesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The company’s 50 day moving average price is $33.37 and its two-hundred day moving average price is $35.07. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 29.53 and a beta of 0.90.

Analysts Set New Price Targets

SUPN has been the topic of several recent research reports. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.